All In Biotech

Drug Trial Radar · NCT06356129

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 850 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

850

Planned (sponsor's estimate)

Start

Jun 19, 2024

Primary completion

Aug 9, 2027

Study completion Jun 26, 2029

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Apr 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).

Conditions

  • Large B-cell Lymphoma

Interventions

  • GolcadomideDrug

    Specified dose on specified days

  • PlaceboDrug

    Specified dose on specified days

  • RituximabDrug

    Specified dose on specified days

  • CyclophosphamideDrug

    Specified dose on specified days

  • DoxorubicinDrug

    Specified dose on specified days

  • VincristineDrug

    Specified dose on specified days

  • PrednisoneDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) assessed by the InvestigatorTime frame: Approximately 24 months after the last participant's first treatment

Locations

325 sites in 38 countries. Site status is shown where the registry gives one.

  • Local Institution - 0014

    Mobile, Alabama

  • Local Institution - 0477

    Anchorage, Alaska

  • Local Institution - 0452

    Phoenix, Arizona

  • Local Institution - 0342

    San Francisco, California

  • Local Institution - 0497

    Fort Myers, Florida

  • Local Institution - 0287

    Jacksonville, Florida

  • Local Institution - 0415

    Margate, Florida

  • Local Institution - 0045

    Miami Beach, Florida

  • Local Institution - 0012

    Pensacola, Florida

  • Local Institution - 0502

    St. Petersburg, Florida

  • Local Institution - 0414

    Tampa, Florida

  • Local Institution - 0192

    West Palm Beach, Florida

  • Local Institution - 0485

    Weston, Florida

  • Local Institution - 0515

    Atlanta, Georgia

  • Local Institution - 0303

    Atlanta, Georgia

  • Local Institution - 0182

    Chicago, Illinois

  • Local Institution - 0048

    Skokie, Illinois

  • Local Institution - 0461

    Waukee, Iowa

  • Local Institution - 0031

    Westwood, Kansas

  • Local Institution - 0436

    Edgewood, Kentucky

  • Local Institution - 0408

    Baton Rouge, Louisiana

  • Local Institution - 0478

    Ann Arbor, Michigan

  • Local Institution - 0067

    Minneapolis, Minnesota

  • Local Institution - 0203

    Rochester, Minnesota

  • Local Institution - 0437

    Kansas City, Missouri

  • Local Institution - 0466

    Reno, Nevada

  • Local Institution - 0498

    East Brunswick, New Jersey

  • Local Institution - 0480

    Hackensack, New Jersey

  • Local Institution - 0049

    Morristown, New Jersey

  • Local Institution - 0175

    New Brunswick, New Jersey

  • Local Institution - 0190

    Buffalo, New York

  • Local Institution - 0451

    East Syracuse, New York

  • Local Institution - 0484

    New York, New York

  • Local Institution - 0369

    New York, New York

  • Local Institution - 0176

    New York, New York

  • Local Institution - 0174

    Chapel Hill, North Carolina

  • Local Institution - 0066

    Massillon, Ohio

  • Local Institution - 0450

    Tulsa, Oklahoma

  • Local Institution - 0179

    Portland, Oregon

  • Local Institution - 0009

    Pittsburgh, Pennsylvania

Showing 40 of 325 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.